| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
Olema Pharmaceuticals (NASDAQ:OLMA) reported quarterly losses of $(0.49) per share which missed the analyst consensus estimate ...
Olema Pharmaceuticals, Inc. (("Olema" or "Olema Oncology", NASDAQ:OLMA), a clinical-stage biopharmaceutical com...
HC Wainwright & Co. analyst Emily Bodnar reiterates Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy and maintains $28 pri...
Palazestrant in combination with ribociclib demonstrated encouraging activity across all dose cohorts and subgroupsMedian PFS w...
Guggenheim analyst Brad Canino initiates coverage on Olema Pharmaceuticals (NASDAQ:OLMA) with a Buy rating and announces Pri...